Copper peptides (GHK-Cu): what the research says. | Reddit

A copper peptide is a small peptide that carries a copper(II) ion. In cosmetics and in the research literature the term almost always means one specific molecule: GHK-Cu, the tripeptide glycine-histidine-lysine complexed with copper. A 2008 review in Journal of Biomaterials Science, Polymer Edition describes GHK as having a copper affinity similar to the copper transport site on albumin, which is why the peptide holds the ion in the first place.

GHK is present in human plasma, saliva and urine, and its level declines with age. That decline, plus the peptide’s appearance at sites of tissue injury, is the observation the whole research program is built on.

In everyday use, yes. “Copper peptide” is the category and GHK-Cu is the molecule almost everyone means by it. The distinction matters in two places: on an ingredient list, where a product may carry copper in another form, and in the research, where GHK and GHK-Cu are studied as separate entities and produce different results.

The proposed model has two halves that are hard to separate: the peptide carries copper into tissue in a form cells can use, and the peptide itself acts as a signal in matrix turnover. Nearly all of the mechanistic work below was done in cell culture or in animals.

This is the most interesting open question in the literature, and it is one most product pages skip. Several results point at copper itself as the active part, while other work reports effects from the peptide with no copper attached. Both strands are real, and they have not been reconciled.

The skin literature is deep in mechanism and thin in controlled human outcomes. A 2025 review in International Journal of Medical Sciences surveys tripeptides in wound repair and skin regeneration, and a review summarises existing research rather than producing a new result. The table below is the honest version of the evidence, sorted by what was studied and in what model.

None of the primary sources cited on this page is a randomised controlled trial of GHK-Cu in people. The closest is the 2020 Journal of Cosmetic Dermatology study, and it used human skin explants cultured outside the body and tested copper ions rather than the GHK complex. That is human tissue, which is closer than a rodent, and it is still not a person applying a cream.

One 2015 paper is sometimes listed among the human literature and is not human at all. It is a rat model of ACL reconstruction: 72 rats randomised to saline or GHK-Cu at 0.3 or 3 mg/mL, with weekly intra-articular injections beginning at week two for four weeks. The paper’s own title reports the improvement as transient.

The wound-repair strand is where GHK-Cu has the most experimental support, and nearly all of it is in animals or in engineered materials rather than in patients. Much of the recent work is really materials science: the peptide is attached to a scaffold or a particle, and the scaffold is part of what is being tested.

Copper peptides appear in scalp serums and hair products, and the case made for them is an extrapolation rather than a finding. None of the primary sources cited on this page studied hair growth, follicle count or shedding. The reasoning runs from the skin and wound work to the follicle, which is a hypothesis, not a result.

Treating that gap as though it were evidence is the single most common error in copper-peptide marketing. It is also easy to check: ask which study, in which model, measured hair.

Three different products get discussed under one name, and they differ in how you get them, what evidence sits behind them and where they stand with the FDA. Collapsing them together is what makes most online copper-peptide arguments unresolvable.

This is the question the formulation literature keeps circling, and it deserves more attention than the ingredient lists give it. A 2025 review in Molecules describes GHK-Cu as fairly hydrophilic with limited permeation through the lipophilic stratum corneum, and frames measuring that permeation as an open methodological problem. A 2025 paper in ACS Applied Materials & Interfaces puts it more bluntly, noting that clinical application has been hindered by poor biological stability and limited efficacy in a physiological medium.

A 2016 preformulation study in Pharmaceutical Development and Technology found the peptide susceptible to hydrolysis under stressed conditions, which is why vehicle, pH and packaging are not trivia on a copper-peptide product.

There is no established timeline for a person using a copper peptide product, because the controlled human studies that would produce one are not in the literature cited here. What does exist are study durations from animal and laboratory work, and those describe an experiment rather than a schedule.

Topical copper peptides have a long history of cosmetic use and the reported issues are local. The injectable picture is different, and the honest statement there is about absence of data rather than reassurance. Unstudied is not the same as safe.

The precise answer is narrower than “legal” or “illegal.” Injectable GHK-Cu is not an FDA-approved drug. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded preparation qualifies for the statute’s exemptions only if its bulk substance has a USP monograph, is a component of an approved drug, or appears on the FDA’s 503A Bulks List. Injectable GHK-Cu has not been placed on that list, so compounding it falls outside those exemptions, which makes the product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture rather than a criminal prohibition. The regulatory notice above states the current classification.

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A Bulks List and recommended six of them: BPC-157, KPV, TB-500, MOTs-C, Semax and Epitalon. Emideltide was rejected. GHK-Cu was not among the seven reviewed. Those votes are advisory and non-binding, nothing was added to the list, and no compound’s status changed.

Topical copper peptides sit in a different framework. Copper tripeptide-1 is sold widely as a cosmetic ingredient, and cosmetic regulation is not drug approval. PepScribe offers GHK-Cu as a topical cream, prescribed by a licensed clinician and compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

Given that permeation and stability are the unsettled parts of the science, the useful questions are about the formulation and the supply chain rather than about the molecule.

If the goal is skin firmness, tone and texture, a clinician-led route replaces the two things a retail purchase cannot supply: a prescriber who reviews your history first, and a licensed pharmacy that prepares a known concentration for you.